{"id":236,"date":"2014-09-05T13:15:15","date_gmt":"2014-09-05T13:15:15","guid":{"rendered":"http:\/\/www.farmacovigilanciacanarias.org\/noticias\/?p=236"},"modified":"2014-09-05T13:15:15","modified_gmt":"2014-09-05T13:15:15","slug":"nota-informativa-muh-fv-132014","status":"publish","type":"post","link":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/2014\/09\/05\/nota-informativa-muh-fv-132014\/","title":{"rendered":"Nota Informativa MUH (FV), 13\/2014"},"content":{"rendered":"<p><a style=\"color: #004878\" href=\"http:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2014\/NI-MUH_FV_13-2014-Denosumab.htm\">Denosumab (Prolia\u00ae, \u25bcXgeva\u00ae): riesgo de osteonecrosis mandibular e hipocalcemia<\/a><span style=\"color: #000000\">\u00a0<\/span><\/p>\n<p><span style=\"color: #ff0000\">Correcci\u00f3n de erratas de 4 de septiembre de 2014<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Denosumab (Prolia\u00ae, \u25bcXgeva\u00ae): riesgo de osteonecrosis mandibular e hipocalcemia\u00a0 Correcci\u00f3n de erratas de 4 de septiembre de 2014<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-236","post","type-post","status-publish","format-standard","hentry","category-seguridad"],"_links":{"self":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/comments?post=236"}],"version-history":[{"count":1,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/236\/revisions"}],"predecessor-version":[{"id":237,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/236\/revisions\/237"}],"wp:attachment":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/media?parent=236"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/categories?post=236"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/tags?post=236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}